

1. Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. *J Exp Clin Cancer Res*. 2018 doi:10.1186/s13046-018-0796-1.
2. Bagnoli M, Canevari S, Califano D, Losito S, Di Maio M, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi MA, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco D, Mezzanzanica D. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. *Lancet Oncol* 2016 Jul 8. pii: S1470-2045(16)30108-5.
3. Sensi M, Canevari S, Tomassetti A. Axl in ovarian cancer: a step forward for clinical breakthrough? *Oncotarget*. 2016 Dec 6;7(49):80105-80106.
4. Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwala ZM, Canevari S, Bagnoli M, Mezzanzanica D. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. *Oncotarget*. 2015 May 10;6(13):11216-30.
5. Rea K, Pinciroli P, Sensi M, Alciato F, Bisaro B, Lozneau L, Raspagliesi F, Centritto F, Cabodi S, Defilippi P, Avanzi GC, Canevari S, Tomassetti A. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. *Oncotarget*. 2015 Oct;6(31):30859-75.
6. De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. *Oncogene*. 2009 Mar 5;28(9):1206-17. doi: 10.1038/onc.2008.470.
7. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. *Clin Cancer Res*. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.
8. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. *Oncogene*. 2012 Sep 13;31(37):4139-49.
9. Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzone A, Raspagliesi F, Oggionni M, Pilotti S, Canevari S. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. *Clin Cancer Res*. 2004 Aug 1;10(15):5202-14.
10. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. *Oncogene*. 2000 Sep 28;19(41):4754-63.